# TET1

Source: https://onco.cc/targets/tet1/  
OnCo record `tet1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TET1 (Methylcytosine dioxygenase TET1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Hepatocellular carcinoma, Testicular germ cell tumours and 5 more.

## Summary

Dioxygenase that plays a key role in active DNA demethylation, by catalysing the sequential oxidation of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC). In addition to its role in DNA demethylation, plays a more general role in chromatin regulation by recruiting histone modifying protein complexes to alter histone marks and chromatin accessibility, leading to both activation and repression of gene expression. Plays therefore a role in many biological processes, including stem cell maintenance, T- and B-cell development, inflammation regulation, genomic imprinting, neural activity or DNA repair.

CIViC holds 1 clinical evidence item and 0 assertions across 2 variants, naming Immune Checkpoint Inhibitor. Open Targets scores its association with cancer at 0.69 (direct and indirect evidence; datatypes literature 0.99, animal model 0.32, genetic association 0.00, somatic mutation 0.89). IntOGen calls it a driver in 8 cohorts (1 activating, 7 loss-of-function), covering Colon Adenocarcinoma, Glioblastoma Multiforme, Hepatocellular Carcinoma, Medulloblastoma, Mixed Germ Cell Tumour, Nasopharyngeal Carcinoma and others.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: tet methylcytosine dioxygenase 1; Methylcytosine dioxygenase TET1; KIAA1676; bA119F7.1; CXXC6
- Tags: cancer-genes-wave
- Symbol: TET1
- Class: transcription
- Biology: Dioxygenase that plays a key role in active DNA demethylation, by catalysing the sequential oxidation of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC). In addition to its role in DNA demethylation, plays a more general role in chromatin regulation by recruiting histone modifying protein complexes to alter histone marks and chromatin accessibility, leading to both activation and repression of gene expression. Plays therefore a role in many biological processes, including stem cell maintenance, T- and B-cell development, inflammation regulation, genomic imprinting, neural activity or DNA repair. Involved in the balance between pluripotency and lineage commitment of cells and plays a role in embryonic stem cells maintenance and inner cell mass cell specification. Together with QSER1, plays an essential role in the protection and maintenance of transcriptional and developmental programs to inhibit the binding of DNMT3A/3B and therefore de novo methylation. May play a role in pancreatic beta-cell specification during development. Location: Nucleus; Chromosome (UniProt). Locus 10q21.3 (HGNC).
- Where found: Colorectal cancer: Open Targets association 0.55 with colorectal cancer (MONDO_0005575); IntOGen driver in 1 cohort (COAD); Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC); Testicular germ cell tumours: IntOGen driver in 1 cohort (MGCT); Nasopharyngeal carcinoma: IntOGen driver in 1 cohort (NPC); Renal cell carcinoma: IntOGen driver in 1 cohort (PRCC); Gastric & gastro-oesophageal junction cancer: IntOGen driver in 1 cohort (STAD)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 7 cohorts; CIViC holds 1 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:29484: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29484
- UniProt Q8NFU7: https://www.uniprot.org/uniprotkb/Q8NFU7/entry
- NCBI Gene 80312: https://www.ncbi.nlm.nih.gov/gene/80312
- Ensembl ENSG00000138336: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138336

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/), [Testicular germ cell tumours](https://onco.cc/cancers/testicular/)

---
JSON: https://onco.cc/api/v1/entities/tet1.json